View Future GrowthKuros Biosciences 過去の業績過去 基準チェック /36Kuros Biosciencesは、平均年間17%の収益成長を遂げていますが、 Biotechs業界の収益は、年間 成長しています。収益は、平均年間36.2% 56.6%収益成長率で 成長しています。 Kuros Biosciencesの自己資本利益率は2.9%であり、純利益率は1.7%です。主要情報16.96%収益成長率21.50%EPS成長率Biotechs 業界の成長17.04%収益成長率56.64%株主資本利益率2.91%ネット・マージン1.69%次回の業績アップデート13 Aug 2026最近の業績更新お知らせ • Aug 16+ 1 more updateKuros Biosciences AG to Report Fiscal Year 2025 Results on Mar 10, 2026Kuros Biosciences AG announced that they will report fiscal year 2025 results on Mar 10, 2026お知らせ • Feb 25+ 1 more updateKuros Biosciences AG to Report Fiscal Year 2024 Results on Mar 11, 2025Kuros Biosciences AG announced that they will report fiscal year 2024 results on Mar 11, 2025お知らせ • Mar 08Kuros Biosciences AG to Report Fiscal Year 2023 Results on Mar 13, 2024Kuros Biosciences AG announced that they will report fiscal year 2023 results on Mar 13, 2024すべての更新を表示Recent updatesお知らせ • Mar 26Kuros Biosciences AG, Annual General Meeting, Apr 15, 2026Kuros Biosciences AG, Annual General Meeting, Apr 15, 2026, at 11:00 W. Europe Standard Time.お知らせ • Mar 10Kuros Biosciences AG Provides Earnings Guidance for the Year 2026-2028Kuros Biosciences AG provided earnings guidance for the year 2026-2028. For the year, the Group expects at least 35% sales growth. By 2028, the Group anticipates sales of USD 300 million to USD 330 million.お知らせ • Oct 16Kuros Biosciences AG Raises earnings Guidance for the Year 2025Kuros Biosciences AG raised earnings guidance for the year 2025. For the year, Group is raising its sales guidance and now expects growth of at least 70% .お知らせ • Sep 04Kuros Biosciences Announces Board and Committee ChangesKuros Biosciences announced that Albert Arp has decided to resign from the Board of Directors with immediate effect for personal and professional reasons. Oliver Walker was appointed as Chair of the Audit and Risk Committee. Kimberley Elting was appointed as member of the Audit and Risk Committee and as member and Chair of the Compensation and Nomination Committee.お知らせ • Aug 16+ 1 more updateKuros Biosciences AG to Report Fiscal Year 2025 Results on Mar 10, 2026Kuros Biosciences AG announced that they will report fiscal year 2025 results on Mar 10, 2026お知らせ • Aug 14Kuros Biosciences Ag Provides Earnings Guidance for the Year 2025 and by 2027Kuros Biosciences AG provided earnings guidance for the year 2025 and by 2027. For the year, the company expects robust sales growth of at least 60% in 2025. Kuros is anticipating sales of USD 220 to 250 million by 2027, reflecting its commitment to long-term value creation through innovation, market share gains, and customer satisfaction.お知らせ • Aug 05Kuros Biosciences Launches Magnetos MIS Delivery System by Completion of the First U.S. Cases Using the New Magnetos MIS Delivery SystemKuros Biosciences announced the completion of the first U.S. cases using the new MagnetOsTM MIS Delivery System - a sterile, prefilled, single-use delivery system engineered for Minimally invasive Surgery in spine procedures. Following FDA 510(k) clearance of the MagnetOs MIS Delivery System in May, these first cases mark a significant milestone in expanding surgeon access to a more streamlined approach for graft delivery. Dr. Daniel Park, orthopedic spine surgeon, performed his first case using the new FDA-cleared system in Southfield, Michigan. MagnetOs MIS builds on the proven science of MagnetOs and its proprietary NeedleGrip submicron surface technology, which harnesses the immune system to stimulate bone growth. It is engineered for precise delivery, surgical efficiency, and predictable fusion outcomes. Compared to delivering MagnetOs in a traditional, funnel-based system, MagnetOs MIS achieved graft placement three times faster, optimizing time in the operating room. The MIS system is supported by robust published clinical evidence for MagnetOs in cases where minimally invasive procedures and surgical site accessibility is crucial. In a retrospective study, MagnetOs achieved a 94.4% fusion rate across 36 levels treated in patients undergoing MIS and open transforaminal lumbar interbody fusions, where the majority of patients had comorbidities such as obesity, smoking, diabetes, or a previous spine surgery. These results build on previously published Level I prospective, randomized, controlled human clinical data demonstrating that MagnetOs achieved nearly twice the fusion rate of autograft in posterolateral fusion (79% vs. 47%). Additionally, and following the recent ANVISA approval of MagnetOs Granules, Kuros also announced that MagnetOs Putty now has been approved by the Brazilian regulatory authority, expanding the company's entry into the South American spine and orthopedic market.お知らせ • Apr 15Kuros Biosciences Ag Elects Kimberley Elting as A New Member of the Board of DirectorsKuros Biosciences AG announced Kimberley Elting was elected as a new member of the Board of Directors.お知らせ • Mar 26Kuros Biosciences AG, Annual General Meeting, Apr 15, 2025Kuros Biosciences AG, Annual General Meeting, Apr 15, 2025, at 11:00 W. Europe Standard Time.お知らせ • Feb 25+ 1 more updateKuros Biosciences AG to Report Fiscal Year 2024 Results on Mar 11, 2025Kuros Biosciences AG announced that they will report fiscal year 2024 results on Mar 11, 2025お知らせ • Oct 10Kuros Biosciences AG Provides Sales Guidance for the Second Half of 2024Kuros Biosciences AG provided sales guidance for the second half of 2024. For the remainder of the second half of 2024, Kuros expects a similar seasonal sales pattern as in previous years, corresponding to around 57% to 60% of total annual sales.お知らせ • Apr 17Kuros Biosciences AG Approves Board of Director and Committee ChangesKuros Biosciences AG at the Annual general meeting approved Board of director and committee changes. Albert Arp and Chris Fair (CEO) were elected as new members of the Board of Directors, Albert Arp was elected as a new member of the Compensation Committee. Scott Bruder did not stand for re-election as member of the board.お知らせ • Mar 08Kuros Biosciences AG to Report Fiscal Year 2023 Results on Mar 13, 2024Kuros Biosciences AG announced that they will report fiscal year 2023 results on Mar 13, 2024お知らせ • Jan 31Kuros Biosciences Receives US FDA 510K Clearance for Magnetos Granules for Interbody Use and Regulatory Clearance of Magnetos Granules and Magnetos Putty in New ZealandKuros Biosciences announced clearance of a 510(k) submission from the U.S. Food and Drug Administration related to its MagnetOs Granules. The Company also announced clearance to market in New Zealand for MagnetOs Granules and MagnetOs Putty. The products are now commercially available through Vortek Spine Limited ("Vortek"), a high-tech orthopedic and biologics company specializing in healthcare solutions for surgeons and patients. This further expands the MagnetOs portfolio in terms of application and accessibility. Earlier in January, Kuros announced the FDA clearance of MagnetOs Easypack Putty for interbody use and MagnetOs Putty for standalone use in the posterolateral spine, meaning it can now be used without the need for autograft (patient's own bone). The availability of MagnetOs in New Zealand marks a significant milestone for Kuros and the local medical community since patients can now benefit from an advanced bone graft that improves the overall quality of care in orthopedic and spinal procedures. This benefit was further demonstrated with recent level 1 clinical data in which MagnetOs outperformed the gold standard autograft by 73% in posterior spinal fusion in a difficult-to-treat real life patient population, of which 20% were current smokers.お知らせ • Nov 29Kuros Biosciences Receives FDA Clearance for Use of Magnetos in Interbody Spinal CagesKuros Biosciences announced that MagnetOs Flex Matrix has been cleared for use in the interbody space by the U.S. Food and Drug Administration (FDA). As a result, it can now be used in any interbody space (cervical, thoracic, lumbar); and in any cage approved for use with a bone void filler. With interbody cages being used in almost half of the estimated 1.5 million instrumented spinal fusion procedures conducted annually in the USA, this news is especially significant for surgeons. MagnetOs Flex Matrix is uniquely well suited to interbody applications. Due to its excellent granule retention, it stays strong yet flexible even when wet - for easy placement either through a funnel or packed directly into any cage, of any size. MagnetOs Flex Matrix is the first Kuros product to receive interbody clearance, having already been cleared by the FDA for use in posterolateral fusions. Due to its unique fibrillar and flexible structure, this open matrix bone graft promotes bone growth even in soft tissue by optimizing the effect of Kuros' established NeedleGrip surface technology.収支内訳Kuros Biosciences の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:CSBT.F 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Dec 2514621081130 Sep 25130-2981030 Jun 25123-796931 Mar 2599-578831 Dec 2485-468830 Jun 2459-649331 Mar 2448-842331 Dec 2340-1238230 Sep 2329-1630830 Jun 2323-1827831 Mar 2321-1724731 Dec 2219-1621630 Sep 2217-1318430 Jun 2216-1217331 Mar 2216-1016431 Dec 2115-815530 Sep 2114-714530 Jun 2113-612531 Mar 218-911431 Dec 205-1311530 Sep 204-1310430 Jun 203-139431 Mar 203-128431 Dec 193-128530 Sep 192-118630 Jun 191-128731 Mar 191-128731 Dec 181-129730 Sep 181-1311430 Jun 180-1513131 Mar 180-1615031 Dec 171-1716030 Sep 171-1515130 Jun 171-1413231 Mar 171-1715131 Dec 161-1917030 Sep 161-1916030 Jun 161-1814031 Mar 161-129031 Dec 150-640質の高い収益: CSBT.Fは 高品質の収益 を持っています。利益率の向上: CSBT.F過去に利益を上げました。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: CSBT.F過去 5 年間で収益を上げており、収益は年間17%増加しています。成長の加速: CSBT.Fは昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。収益対業界: CSBT.F昨年収益を上げたため、昨年の収益成長をBiotechs業界 ( 54.5% ) と比較することは困難です。株主資本利益率高いROE: CSBT.Fの 自己資本利益率 ( 2.9% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/12 08:57終値2026/06/08 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Kuros Biosciences AG 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Volker BosseBaader Helvea Equity ResearchThomas MeyerBaader Helvea Equity Research
お知らせ • Aug 16+ 1 more updateKuros Biosciences AG to Report Fiscal Year 2025 Results on Mar 10, 2026Kuros Biosciences AG announced that they will report fiscal year 2025 results on Mar 10, 2026
お知らせ • Feb 25+ 1 more updateKuros Biosciences AG to Report Fiscal Year 2024 Results on Mar 11, 2025Kuros Biosciences AG announced that they will report fiscal year 2024 results on Mar 11, 2025
お知らせ • Mar 08Kuros Biosciences AG to Report Fiscal Year 2023 Results on Mar 13, 2024Kuros Biosciences AG announced that they will report fiscal year 2023 results on Mar 13, 2024
お知らせ • Mar 26Kuros Biosciences AG, Annual General Meeting, Apr 15, 2026Kuros Biosciences AG, Annual General Meeting, Apr 15, 2026, at 11:00 W. Europe Standard Time.
お知らせ • Mar 10Kuros Biosciences AG Provides Earnings Guidance for the Year 2026-2028Kuros Biosciences AG provided earnings guidance for the year 2026-2028. For the year, the Group expects at least 35% sales growth. By 2028, the Group anticipates sales of USD 300 million to USD 330 million.
お知らせ • Oct 16Kuros Biosciences AG Raises earnings Guidance for the Year 2025Kuros Biosciences AG raised earnings guidance for the year 2025. For the year, Group is raising its sales guidance and now expects growth of at least 70% .
お知らせ • Sep 04Kuros Biosciences Announces Board and Committee ChangesKuros Biosciences announced that Albert Arp has decided to resign from the Board of Directors with immediate effect for personal and professional reasons. Oliver Walker was appointed as Chair of the Audit and Risk Committee. Kimberley Elting was appointed as member of the Audit and Risk Committee and as member and Chair of the Compensation and Nomination Committee.
お知らせ • Aug 16+ 1 more updateKuros Biosciences AG to Report Fiscal Year 2025 Results on Mar 10, 2026Kuros Biosciences AG announced that they will report fiscal year 2025 results on Mar 10, 2026
お知らせ • Aug 14Kuros Biosciences Ag Provides Earnings Guidance for the Year 2025 and by 2027Kuros Biosciences AG provided earnings guidance for the year 2025 and by 2027. For the year, the company expects robust sales growth of at least 60% in 2025. Kuros is anticipating sales of USD 220 to 250 million by 2027, reflecting its commitment to long-term value creation through innovation, market share gains, and customer satisfaction.
お知らせ • Aug 05Kuros Biosciences Launches Magnetos MIS Delivery System by Completion of the First U.S. Cases Using the New Magnetos MIS Delivery SystemKuros Biosciences announced the completion of the first U.S. cases using the new MagnetOsTM MIS Delivery System - a sterile, prefilled, single-use delivery system engineered for Minimally invasive Surgery in spine procedures. Following FDA 510(k) clearance of the MagnetOs MIS Delivery System in May, these first cases mark a significant milestone in expanding surgeon access to a more streamlined approach for graft delivery. Dr. Daniel Park, orthopedic spine surgeon, performed his first case using the new FDA-cleared system in Southfield, Michigan. MagnetOs MIS builds on the proven science of MagnetOs and its proprietary NeedleGrip submicron surface technology, which harnesses the immune system to stimulate bone growth. It is engineered for precise delivery, surgical efficiency, and predictable fusion outcomes. Compared to delivering MagnetOs in a traditional, funnel-based system, MagnetOs MIS achieved graft placement three times faster, optimizing time in the operating room. The MIS system is supported by robust published clinical evidence for MagnetOs in cases where minimally invasive procedures and surgical site accessibility is crucial. In a retrospective study, MagnetOs achieved a 94.4% fusion rate across 36 levels treated in patients undergoing MIS and open transforaminal lumbar interbody fusions, where the majority of patients had comorbidities such as obesity, smoking, diabetes, or a previous spine surgery. These results build on previously published Level I prospective, randomized, controlled human clinical data demonstrating that MagnetOs achieved nearly twice the fusion rate of autograft in posterolateral fusion (79% vs. 47%). Additionally, and following the recent ANVISA approval of MagnetOs Granules, Kuros also announced that MagnetOs Putty now has been approved by the Brazilian regulatory authority, expanding the company's entry into the South American spine and orthopedic market.
お知らせ • Apr 15Kuros Biosciences Ag Elects Kimberley Elting as A New Member of the Board of DirectorsKuros Biosciences AG announced Kimberley Elting was elected as a new member of the Board of Directors.
お知らせ • Mar 26Kuros Biosciences AG, Annual General Meeting, Apr 15, 2025Kuros Biosciences AG, Annual General Meeting, Apr 15, 2025, at 11:00 W. Europe Standard Time.
お知らせ • Feb 25+ 1 more updateKuros Biosciences AG to Report Fiscal Year 2024 Results on Mar 11, 2025Kuros Biosciences AG announced that they will report fiscal year 2024 results on Mar 11, 2025
お知らせ • Oct 10Kuros Biosciences AG Provides Sales Guidance for the Second Half of 2024Kuros Biosciences AG provided sales guidance for the second half of 2024. For the remainder of the second half of 2024, Kuros expects a similar seasonal sales pattern as in previous years, corresponding to around 57% to 60% of total annual sales.
お知らせ • Apr 17Kuros Biosciences AG Approves Board of Director and Committee ChangesKuros Biosciences AG at the Annual general meeting approved Board of director and committee changes. Albert Arp and Chris Fair (CEO) were elected as new members of the Board of Directors, Albert Arp was elected as a new member of the Compensation Committee. Scott Bruder did not stand for re-election as member of the board.
お知らせ • Mar 08Kuros Biosciences AG to Report Fiscal Year 2023 Results on Mar 13, 2024Kuros Biosciences AG announced that they will report fiscal year 2023 results on Mar 13, 2024
お知らせ • Jan 31Kuros Biosciences Receives US FDA 510K Clearance for Magnetos Granules for Interbody Use and Regulatory Clearance of Magnetos Granules and Magnetos Putty in New ZealandKuros Biosciences announced clearance of a 510(k) submission from the U.S. Food and Drug Administration related to its MagnetOs Granules. The Company also announced clearance to market in New Zealand for MagnetOs Granules and MagnetOs Putty. The products are now commercially available through Vortek Spine Limited ("Vortek"), a high-tech orthopedic and biologics company specializing in healthcare solutions for surgeons and patients. This further expands the MagnetOs portfolio in terms of application and accessibility. Earlier in January, Kuros announced the FDA clearance of MagnetOs Easypack Putty for interbody use and MagnetOs Putty for standalone use in the posterolateral spine, meaning it can now be used without the need for autograft (patient's own bone). The availability of MagnetOs in New Zealand marks a significant milestone for Kuros and the local medical community since patients can now benefit from an advanced bone graft that improves the overall quality of care in orthopedic and spinal procedures. This benefit was further demonstrated with recent level 1 clinical data in which MagnetOs outperformed the gold standard autograft by 73% in posterior spinal fusion in a difficult-to-treat real life patient population, of which 20% were current smokers.
お知らせ • Nov 29Kuros Biosciences Receives FDA Clearance for Use of Magnetos in Interbody Spinal CagesKuros Biosciences announced that MagnetOs Flex Matrix has been cleared for use in the interbody space by the U.S. Food and Drug Administration (FDA). As a result, it can now be used in any interbody space (cervical, thoracic, lumbar); and in any cage approved for use with a bone void filler. With interbody cages being used in almost half of the estimated 1.5 million instrumented spinal fusion procedures conducted annually in the USA, this news is especially significant for surgeons. MagnetOs Flex Matrix is uniquely well suited to interbody applications. Due to its excellent granule retention, it stays strong yet flexible even when wet - for easy placement either through a funnel or packed directly into any cage, of any size. MagnetOs Flex Matrix is the first Kuros product to receive interbody clearance, having already been cleared by the FDA for use in posterolateral fusions. Due to its unique fibrillar and flexible structure, this open matrix bone graft promotes bone growth even in soft tissue by optimizing the effect of Kuros' established NeedleGrip surface technology.